Darren Kelly

Darren brings a wealth of management and research expertise in the life sciences and biotech sector. Concurrent to his role with OccuRx, Darren is the Managing Director of Certa therapeutics, Venture partner (Entrepreneur in residence) with Brandon Capital, a Board Director at the Centre for Eye Research Australia (CERA) and the Director Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne.

Darren has proven history in translational research having published more than 200 manuscripts. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.

Darren has a PhD in Translational Medicine from the University of Melbourne. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.